All Oncology News

Camizestrant Plus CDK4/6 Inhibition Causes Minimal Effect on Visual QOL in HR+, ESR1-Mutated Breast Cancer

November 7th 2025

Use of camizestrant plus a CDK4/6 inhibitor at the emergence of an ESR1 mutation did not significantly worsen visual symptoms in HR-positive breast cancer.

Giredestrant/Everolimus Opens Doors for Improved SERD Regimens for ER+, Endocrine-Resistant Breast Cancer

November 7th 2025

Erica L. Mayer, MD, MPH, discusses data with giredestrant and how the evERA trial shows the potential for SERD-based regimens in ER-positive breast cancer.

Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma

November 7th 2025

Protein METTL7A plays key role in resistance to drugs targeting EGFR-mutant lung adenocarcinoma.

First-Line Sacituzumab Govitecan After Endocrine Therapy Fails to Improve PFS in HR+/HER2-Negative Breast Cancer

November 7th 2025

The phase 3 ASCENT-07 trial did not meet its primary PFS end point with first-line sacituzumab govitecan in hormone receptor–positive, HER2-negative breast cancer.

FDA Approves Generic Dasatinib Tablets for CML, ALL

November 7th 2025

The FDA has approved generic dasatinib tablets for select patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Darovasertib Plus Crizotinib Could Represent Systemic Therapy Intended for Broader Metastatic Uveal Melanoma Population

November 7th 2025

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

BVd Approval Reframes Considerations Around Sequencing BCMA-Targeted Therapies in R/R Myeloma

November 7th 2025

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

FDA Approves Subcutaneous Daratumumab for High-Risk Smoldering Multiple Myeloma

November 6th 2025

The FDA has approved daratumumab and hyaluronidase-fihj for the treatment of adult patients with high-risk smoldering multiple myeloma.

GFH375 Yields Responses, Disease Control in Heavily Pretreated KRAS G12D+ PDAC

November 6th 2025

GFH375 produced responses and tumor shrinkage in heavily pretreated pancreatic ductal adenocarcinoma harboring KRAS G12D mutations.

Comprehensive Molecular Profiling of Renal Medullary Carcinoma Identifies TROP2 As a Promising Therapeutic Target

November 6th 2025

Researchers conducted the largest, most comprehensive molecular analysis of RMC, leading to the identification of TROP2 as a promising therapeutic target.

Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC

November 6th 2025

Treatment with adjuvant durvalumab plus tremelimumab resulted in a DFS benefit vs active monitoring in RCC, particularly in the higher-risk population.

UGN-103 Yields High 3-Month CR Rate in Low-Grade, Intermediate-Risk NMIBC

November 6th 2025

UGN-103 produced a 77.8% 3-month CR rate in patients with low-grade, intermediate-risk NMIBC.

ChatGPT Fails to Provide Up-to-Date and Specific Information for Specific Queries in Hematologic Malignancies

November 6th 2025

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.

Oncology Fellows Spotlights Recent Grant and Award Winners

November 6th 2025

Oncology Fellows reports recent hematology/oncology fellows grant and award winners and looks ahead to upcoming grants.

Phase 3 KEYNOTE-905 and IMvigor011 Trials Signal New Standards in MIBC

November 6th 2025

Daniel P. Petrylak, MD, discusses key data in MIBC presented during the 2025 ESMO Congress and previews the 19th Annual New York GU Cancers Congress.

177Lu-edotreotide Displays Efficacy Benefit Across Subgroups in Grade 1/2, SSTR+ GEP-NETs

November 6th 2025

Treatment with 177Lu-edotreotide was linked to improvements in PFS and ORR across subgroups of patients with SSTR-positive GEP-NETs.

CSF1R Blockade With AMB-05X May Improve Tumor Control in ctDNA+ CRC

November 5th 2025

A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.

JAK Inhibitor Selection and Sequencing Strategies Are Key in Myelofibrosis Management

November 5th 2025

Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.

Sneaky Senescent Cells That Resist Cancer Treatment Can Provide Druggable Lung Cancer Target

November 5th 2025

FDA Grants Orphan Drug Designation to M2T-CD33 for Acute Myeloid Leukemia

November 5th 2025

The FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.